Zydus Cadila Healthcare has signed an agreement with Medicure’s subsidiary Medicure International for the commercialisation of its ZYPITAMAG (pitavastatin magnesium) drug, which is indicated for managing cholesterol levels, in the US.
The new drug application for the drug, which will be Zydus’ first branded product to be launched in the US, will be held by Zydus, while sales and marketing will be the responsibilities of Medicure, as part of the agreement.
The agreement is expected to enable the commercialisation of ZYPITAMAG.
Eisai and Merck & Co have signed a strategic agreement for LENVIMA (lenvatinib mesylate), which was discovered by the former.
The agreement is meant for the worldwide co-development and co-commercialisation of the drug.
The drug is an orally available tyrosine kinase inhibitor and will be developed jointly by the two companies as monotherapy, as well as a combination therapy with Merck’s anti-PD-1 therapy, KEYTRUDA (pembrolizumab).
New clinical studies on the combination therapy to evaluate 11 potential indications in six types of cancer will also be initiated by the two companies. Furthermore, a basket trial will be conducted targeting multiple cancer types.
The gross profits earned from the drug’s sales will be shared equally by the two companies.
LENVIMA is already approved as a monotherapy for thyroid cancer treatment. It is also approved in combination with everolimus for renal cell carcinoma treatment in patients who have failed previous therapy.
Eisai is a pharmaceutical company, while Merck is a biopharmaceutical company.
Generic pharmaceuticals manufacturer Tabuk Pharmaceuticals Manufacturing Company has been chosen by Renapharma to distribute the latter’s Cholecalciferol Vitamin D3 drops Detremin.
A distribution agreement has also been signed by the companies.
Tabuk has obtained exclusive rights to commercialise and distribute the drops in the Kingdom of Saudi Arabia.
TaiwanJ Pharmaceuticals has raised TWD100m ($3.4m) through a public offering of shares.
The offering included ten million shares priced at TWD10 ($0.34) a share.
Valeant Pharmaceuticals International plans for multiple public offerings of securities including common shares, preferred shares, debt securities, warrants, purchase contacts and units from time to time to raise funds required for general corporate purposes.
The proceeds will be used for working capital, debt repayment, and to explore inorganic and other business opportunities.
Johnson & Johnsons’ pharmaceutical subsidiary Janssen Pharmaceutica NV and Pharmstandard, will together advance ongoing efforts to tackle multi-drug-resistant tuberculosis (MDR-TB).
A memorandum of understanding (MOU) for the same has been signed between the two companies.
Pharmstandard’s Ufimsky Vitamin Plant will be appointed as an additional toll manufacturer for Janssen’s Sirturo (bedaquiline) drug, which is used for the treatment of pulmonary MDR-TB in adults.
Wuchan Zhongda Group has reached an agreement to sell its pharmaceutical subsidiary to Ningbo Menovo Pharmaceutical.
Based in China, Wuchan Zhongda Group is engaged in the import and export of metal materials, chemicals, and coal.
Also based in China, Ningbo Menovo Pharmaceutical is a pharmaceutical company.
Celgene has announced that it has successfully completed the acquisition of Juno Therapeutics, following a definitive merger agreement signed in January.
The acquisition involved a consideration of $9bn, representing $87 a share.
It is expected to strengthen Celgene’s position in the haematology market, while Juno expects the transaction to support its growth.